Shannon Rivera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shannon Rivera has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Xuanwen Li
Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
5 shared publications - Alyssa Quencer Stiving
Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
4 shared publications - Taku Tsukidate
Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
4 shared publications - Ansuman Sahoo
Biologics Process Research & Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
2 shared publications Jonathan Welch
Biologics Analytical Research & Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
2 shared publications- Sri Ranganayaki Madabhushi
Biologics Process Research & Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
2 shared publications
Latest Publications
- 13 November 2026
- Published by Wiley in Electrophoresis
Unexpected Peaks in Reduced Capillary Gel Electrophoresis Associated With Hair and Dust Contamination
Capillary gel electrophoresis (CGE) is a size‐based analytical technique used for monitoring the critical quality attribute of molecular fragmentation. The ability to distinguish protein degradation from method artifacts remains an industry‐wide challenge, driving the need to better understand contributing factors of atypical peak formations. One relatively uncharacterized contributor is contamination introduced during sample preparation. Despite standard operating protocols, analytical method protocols, and implementation of best practices, it is still possible to unintentionally introduce contamination. Two known yet subtle sources of relevant contaminants are hair from the analyst performing the experiment and dust present within the laboratory. Here, we explored the impact of hair and dust contamination in CGE across three different monoclonal antibodies (mAbs) designated as mAb 1, mAb 2, and mAb 3. Through a series of practical experimentation assays, including contaminant spiking experiments and timecourse assessments, six new peaks were identified with a direct correlation to the introduction of hair and dust contaminants. The six peaks were highly reproducible under reducing conditions but not observed in identical tests under nonreducing conditions. This suggests a reducing agent, such as beta‐mercaptoethanol, is required for the formation of Peaks 1–6. Proteolytic activity was also assessed through enzymatic digestion and activity assays. Our data found no evidence of protease involvement, suggesting the peaks are not a result of protein degradation. The relative abundances of corresponding light chains and heavy chains remained consistent, whereas new abundances were observed for Peaks 1–6. One potential suspect was keratin, a fibrous protein that serves as the foundation for hair and could be present in dust. Peptide mapping confirmed an increase in abundance of keratin peptides for samples treated with hair compared to untreated controls. This work highlights a realistic application where the unintentional introduction of hair or dust into CGE samples could produce additional peaks.
- 13 November 2026
- Published by Wiley in Electrophoresis
Unexpected Peaks in Reduced Capillary Gel Electrophoresis Associated With Hair and Dust Contamination
Capillary gel electrophoresis (CGE) is a size‐based analytical technique used for monitoring the critical quality attribute of molecular fragmentation. The ability to distinguish protein degradation from method artifacts remains an industry‐wide challenge, driving the need to better understand contributing factors of atypical peak formations. One relatively uncharacterized contributor is contamination introduced during sample preparation. Despite standard operating protocols, analytical method protocols, and implementation of best practices, it is still possible to unintentionally introduce contamination. Two known yet subtle sources of relevant contaminants are hair from the analyst performing the experiment and dust present within the laboratory. Here, we explored the impact of hair and dust contamination in CGE across three different monoclonal antibodies (mAbs) designated as mAb 1, mAb 2, and mAb 3. Through a series of practical experimentation assays, including contaminant spiking experiments and timecourse assessments, six new peaks were identified with a direct correlation to the introduction of hair and dust contaminants. The six peaks were highly reproducible under reducing conditions but not observed in identical tests under nonreducing conditions. This suggests a reducing agent, such as beta‐mercaptoethanol, is required for the formation of Peaks 1–6. Proteolytic activity was also assessed through enzymatic digestion and activity assays. Our data found no evidence of protease involvement, suggesting the peaks are not a result of protein degradation. The relative abundances of corresponding light chains and heavy chains remained consistent, whereas new abundances were observed for Peaks 1–6. One potential suspect was keratin, a fibrous protein that serves as the foundation for hair and could be present in dust. Peptide mapping confirmed an increase in abundance of keratin peptides for samples treated with hair compared to untreated controls. This work highlights a realistic application where the unintentional introduction of hair or dust into CGE samples could produce additional peaks.
- 4 May 2026
- Published by Elsevier in Journal of Biotechnology
- Vol. 416, 116-124
Leveraging mixed-mode filter during cell culture harvest to prevent antibody reduction
- 4 May 2026
- Published by Elsevier in Journal of Biotechnology
- Vol. 416, 116-124
Leveraging mixed-mode filter during cell culture harvest to prevent antibody reduction
- 28 August 2025
- Published by Wiley in Biotechnology Progress
- Vol. 41 (6) , e70068
Elucidation of cell culture impacts on hydroxylysine levels in monoclonal antibodies using high‐throughput analytical quantification and media components
Hydroxylysine (Hyl) is a post‐translational hydroxyl modification of lysine that is not commonly observed at very high levels and thus is not usually considered a product quality attribute (PQA). Post‐translation modifications (PTMs) are considered potential PQAs when elevated levels are observed – requiring monitoring and investigation. In a recent monoclonal antibody expression using Media A, Hyl levels were observed at ~20%–35%. At such elevated percentage levels, Hyl was considered a PQA – triggering a root‐cause investigation in the upstream activities like cell culture conditions and media components. Initial detection of the Hyl modification originated from non‐quantitative, intact mass analysis with confirmation of site‐location determined by peptide mapping. Through the root‐cause investigation, it was determined that levels of Hyl were underestimated by ~10‐fold using tryptic peptide mapping analysis without inclusion of miscleaved peptides. The analytical procedure was revised from trypsin‐digestion to IdeS‐digestion, a reduced mass analysis, to accurately and rapidly quantify Hyl levels of investigational samples. Proprietary Media B was utilized to reduce the Hyl level by 2‐fold to ~10%–15%. Further investigation into the media and feed components determined that increasing concentration of Fe(III) content decreased Hyl levels. Supplementation of Fe(III) served as a robust mitigation strategy of Hyl reduction in upstream process. Media B was used to scale up to a 500 L bioreactor while maintaining the lower Hyl level. The analytical and cell culture methods developed in this study can be leveraged to detect and tune Hyl levels.
- 28 August 2025
- Published by Wiley in Biotechnology Progress
- Vol. 41 (6) , e70068
Elucidation of cell culture impacts on hydroxylysine levels in monoclonal antibodies using high‐throughput analytical quantification and media components
Hydroxylysine (Hyl) is a post‐translational hydroxyl modification of lysine that is not commonly observed at very high levels and thus is not usually considered a product quality attribute (PQA). Post‐translation modifications (PTMs) are considered potential PQAs when elevated levels are observed – requiring monitoring and investigation. In a recent monoclonal antibody expression using Media A, Hyl levels were observed at ~20%–35%. At such elevated percentage levels, Hyl was considered a PQA – triggering a root‐cause investigation in the upstream activities like cell culture conditions and media components. Initial detection of the Hyl modification originated from non‐quantitative, intact mass analysis with confirmation of site‐location determined by peptide mapping. Through the root‐cause investigation, it was determined that levels of Hyl were underestimated by ~10‐fold using tryptic peptide mapping analysis without inclusion of miscleaved peptides. The analytical procedure was revised from trypsin‐digestion to IdeS‐digestion, a reduced mass analysis, to accurately and rapidly quantify Hyl levels of investigational samples. Proprietary Media B was utilized to reduce the Hyl level by 2‐fold to ~10%–15%. Further investigation into the media and feed components determined that increasing concentration of Fe(III) content decreased Hyl levels. Supplementation of Fe(III) served as a robust mitigation strategy of Hyl reduction in upstream process. Media B was used to scale up to a 500 L bioreactor while maintaining the lower Hyl level. The analytical and cell culture methods developed in this study can be leveraged to detect and tune Hyl levels.
- 21 November 2024
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 35 (12) , 3256-3264
Systematic Optimization of Activity-Based Protein Profiling for Identification of Polysorbate-Degradative Enzymes in Biotherapeutic Drug Substance down to 10 ppb
The identification and control of high-risk host cell proteins (HCPs) in biotherapeutics development are crucial for ensuring product quality and shelf life. Specifically, HCPs with hydrolase activity can cause the degradation of excipient polysorbates (PS), leading to a decrease in the shelf life of the drug product. In this study, we systematically optimized every step of an activity-based protein profiling (ABPP) workflow to identify trace amounts of active polysorbate-degradative enzymes (PSDEs) in biotherapeutic process intermediates. Evaluation of various parameters during sample preparation pinpointed the optimal pH level and fluorophosphonate (FP)-biotin concentration. Moreover, the combined use of a short liquid chromatography gradient and the fast-scanning parallel accumulation-serial fragmentation (PASEF) methodology increased sample throughput without compromising identification coverage. Tuning the trapped ion mobility spectrometry (TIMS) parameters further enhanced sensitivity. In addition, we evaluated various data acquisition modes, including PASEF combined with data-dependent acquisition (DDA PASEF), data-independent acquisition (diaPASEF), or parallel reaction monitoring (prm-PASEF). By employing the newly optimized ABPP workflow, we successfully identified PSDEs at a concentration as low as 10 ppb in a drug substance sample. Finally, the new workflow enabled us to detect a PSDE that could not be detected with the original workflow during a PS degradation root-cause investigation.
- 21 November 2024
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 35 (12) , 3256-3264
Systematic Optimization of Activity-Based Protein Profiling for Identification of Polysorbate-Degradative Enzymes in Biotherapeutic Drug Substance down to 10 ppb
The identification and control of high-risk host cell proteins (HCPs) in biotherapeutics development are crucial for ensuring product quality and shelf life. Specifically, HCPs with hydrolase activity can cause the degradation of excipient polysorbates (PS), leading to a decrease in the shelf life of the drug product. In this study, we systematically optimized every step of an activity-based protein profiling (ABPP) workflow to identify trace amounts of active polysorbate-degradative enzymes (PSDEs) in biotherapeutic process intermediates. Evaluation of various parameters during sample preparation pinpointed the optimal pH level and fluorophosphonate (FP)-biotin concentration. Moreover, the combined use of a short liquid chromatography gradient and the fast-scanning parallel accumulation-serial fragmentation (PASEF) methodology increased sample throughput without compromising identification coverage. Tuning the trapped ion mobility spectrometry (TIMS) parameters further enhanced sensitivity. In addition, we evaluated various data acquisition modes, including PASEF combined with data-dependent acquisition (DDA PASEF), data-independent acquisition (diaPASEF), or parallel reaction monitoring (prm-PASEF). By employing the newly optimized ABPP workflow, we successfully identified PSDEs at a concentration as low as 10 ppb in a drug substance sample. Finally, the new workflow enabled us to detect a PSDE that could not be detected with the original workflow during a PS degradation root-cause investigation.
- Open Access
Systematic Optimization of Activity-Based Protein Profiling for Identification of Polysorbate-Degradative Enzymes in Biotherapeutic Drug Substance Down to 10 ppb
The identification and control of high-risk host cell proteins (HCPs) in biotherapeutics development is crucial for ensuring product quality and shelf life. Specifically, HCPs with hydrolase activity can cause degradation of excipient polysorbates (PS), leading to a decrease in the shelf life of the drug product. In this study, we systematically optimized every step of an activity-based protein profiling (ABPP) workflow to identify trace amounts of active polysorbate-degradative enzymes (PSDEs) in biotherapeutics process intermediates. Evaluation of various parameters during sample preparation pinpointed optimal pH level and fluorophosphonate (FP)-biotin concentration. Moreover, the combined use of a short liquid chromatography gradient and the fast-scanning Parallel Accumulation Serial Fragmentation (PASEF) methodology increased sample throughput without compromising identification coverage. Tuning Trapped Ion Mobility Spectrometry (TIMS) parameters further enhanced sensitivity. In addition, we evaluated various data acquisition modes including PASEF combined with data-dependent acquisition (DDA PASEF), data-independent acquisition (diaPASEF), or parallel reaction monitoring (prm-PASEF). By employing the newly optimized ABPP workflow, we successfully identified PSDEs at a concentration as low as 10 parts per billion (ppb) in a drug substance sample. Finally, the new workflow enabled us to detect a PSDE that could not be detected with the original workflow during a PS degradation root-cause investigation.
Open AccessSystematic Optimization of Activity-Based Protein Profiling for Identification of Polysorbate-Degradative Enzymes in Biotherapeutic Drug Substance Down to 10 ppb
The identification and control of high-risk host cell proteins (HCPs) in biotherapeutics development is crucial for ensuring product quality and shelf life. Specifically, HCPs with hydrolase activity can cause degradation of excipient polysorbates (PS), leading to a decrease in the shelf life of the drug product. In this study, we systematically optimized every step of an activity-based protein profiling (ABPP) workflow to identify trace amounts of active polysorbate-degradative enzymes (PSDEs) in biotherapeutics process intermediates. Evaluation of various parameters during sample preparation pinpointed optimal pH level and fluorophosphonate (FP)-biotin concentration. Moreover, the combined use of a short liquid chromatography gradient and the fast-scanning Parallel Accumulation Serial Fragmentation (PASEF) methodology increased sample throughput without compromising identification coverage. Tuning Trapped Ion Mobility Spectrometry (TIMS) parameters further enhanced sensitivity. In addition, we evaluated various data acquisition modes including PASEF combined with data-dependent acquisition (DDA PASEF), data-independent acquisition (diaPASEF), or parallel reaction monitoring (prm-PASEF). By employing the newly optimized ABPP workflow, we successfully identified PSDEs at a concentration as low as 10 parts per billion (ppb) in a drug substance sample. Finally, the new workflow enabled us to detect a PSDE that could not be detected with the original workflow during a PS degradation root-cause investigation.
- Open Access
- 26 July 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (32) , 12999-13006
diaPASEF Enables High-Throughput Proteomic Analysis of Host Cell Proteins for Biopharmaceutical Process Development
Monitoring and quantifying host cell proteins (HCPs) in biotherapeutic production processes is crucial to ensure product quality, stability, and safety. Liquid chromatography-mass spectrometry (LC-MS) analysis has emerged as an important tool for identifying and quantifying individual HCPs. However, LC-MS-based approaches face challenges due to the wide dynamic range between HCPs and the therapeutic protein as well as laborious sample preparation and long instrument time. To address these limitations, we evaluated the application of parallel accumulation-serial fragmentation combined with data-independent acquisition (diaPASEF) to HCP analysis for biopharmaceutical process development applications. We evaluated different library generation strategies and LC methods, demonstrating the suitability of these workflows for various HCP analysis needs, such as in-depth characterization and high-throughput analysis of process intermediates. Remarkably, the diaPASEF approach enabled the quantification of hundreds of HCPs that were undetectable by a standard data-dependent acquisition mode while considerably improving sample requirement, throughput, coverage, quantitative precision, and data completeness.
- 26 July 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (32) , 12999-13006
Open AccessdiaPASEF Enables High-Throughput Proteomic Analysis of Host Cell Proteins for Biopharmaceutical Process Development
Monitoring and quantifying host cell proteins (HCPs) in biotherapeutic production processes is crucial to ensure product quality, stability, and safety. Liquid chromatography-mass spectrometry (LC-MS) analysis has emerged as an important tool for identifying and quantifying individual HCPs. However, LC-MS-based approaches face challenges due to the wide dynamic range between HCPs and the therapeutic protein as well as laborious sample preparation and long instrument time. To address these limitations, we evaluated the application of parallel accumulation-serial fragmentation combined with data-independent acquisition (diaPASEF) to HCP analysis for biopharmaceutical process development applications. We evaluated different library generation strategies and LC methods, demonstrating the suitability of these workflows for various HCP analysis needs, such as in-depth characterization and high-throughput analysis of process intermediates. Remarkably, the diaPASEF approach enabled the quantification of hundreds of HCPs that were undetectable by a standard data-dependent acquisition mode while considerably improving sample requirement, throughput, coverage, quantitative precision, and data completeness.
- Open Access
diaPASEF Enables High-throughput Proteomic Analysis of Host Cell Proteins for Biopharmaceutical Process Development
Monitoring and quantifying host cell proteins (HCPs) in biotherapeutics production processes is crucial to ensure product quality, stability, and safety. Liquid chromatography–mass spectrometry (LC–MS) analysis has emerged as an important tool for identifying and quantifying individual HCPs. However, LC-MS–based approaches face challenges due to the wide dynamic range between HCPs and the therapeutic protein, as well as laborious sample preparation and long instrument time. To address these limitations, we evaluated the application of parallel accumulation–serial fragmentation combined with data-independent acquisition (diaPASEF), to HCP analysis for biopharmaceutical process development applications. We evaluated different library generation strategies and LC methods, demonstrating the suitability of these workflows for various HCP analysis needs such as in-depth characterization and high-throughput analysis of process intermediates. Remarkably, the diaPASEF approach enabled the quantification of hundreds of HCPs that were undetectable by a standard data-dependent acquisition mode while considerably improving sample requirement, throughput, coverage, quantitative precision, and data completeness.
Open AccessdiaPASEF Enables High-throughput Proteomic Analysis of Host Cell Proteins for Biopharmaceutical Process Development
Monitoring and quantifying host cell proteins (HCPs) in biotherapeutics production processes is crucial to ensure product quality, stability, and safety. Liquid chromatography–mass spectrometry (LC–MS) analysis has emerged as an important tool for identifying and quantifying individual HCPs. However, LC-MS–based approaches face challenges due to the wide dynamic range between HCPs and the therapeutic protein, as well as laborious sample preparation and long instrument time. To address these limitations, we evaluated the application of parallel accumulation–serial fragmentation combined with data-independent acquisition (diaPASEF), to HCP analysis for biopharmaceutical process development applications. We evaluated different library generation strategies and LC methods, demonstrating the suitability of these workflows for various HCP analysis needs such as in-depth characterization and high-throughput analysis of process intermediates. Remarkably, the diaPASEF approach enabled the quantification of hundreds of HCPs that were undetectable by a standard data-dependent acquisition mode while considerably improving sample requirement, throughput, coverage, quantitative precision, and data completeness.